Relevance of CYP2D6 -1584C>G polymorphism for thioridazine:mesoridazine plasma concentration ratio in psychiatric patients

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1083-1089

  Dorado, Pedro ^a   Peñas LLedo, Eva M ^a   De La Rubia, Alfredo ^b   Llerena, Adrián ^a,c  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b Hospital de Merida   (Spain)

^c Departamento de Matemática   (Portugal)

Author keywords

Antipsychotic drugs; CYP2D6; Mesoridazine; Phenotiazines; Thioridazine

Indexed keywords

CYTIDINE; CYTOCHROME P450 2D6; GUANOSINE; MESORIDAZINE; THIORIDAZINE;

CAUCASIAN; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MONOTHERAPY; MORNING DOSAGE; PERSONALITY DISORDER; PHARMACOGENETICS; SCHIZOPHRENIA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HETEROZYGOTE DETECTION; HUMANS; MALE; MENTAL DISORDERS; MESORIDAZINE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; SUBSTRATE SPECIFICITY; THIORIDAZINE;

EID: 70449515533     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.57     Document Type: Conference Paper

References (23)

1. Lin G, Hawes EM, McKay G, Korchinski ED, Midha KK: Metabolism of piperidine-type phenothiazine antipsychotic agents. IV. Thioridazine in dog, man and rat. Xenobiotica 23(10), 1059-1074 (1993).
2. Kilts CD, Knight DL, Mailman RB, Widerlov E, Breese GR: Effects of thioridazine and its metabolites on dopaminergic function: drug metabolism as a determinant of the antidopaminergic actions of thioridazine. J. Pharmacol. Exp. Ther. 231(12), 334-342 (1984).
3. Wojcikowski J, Maurel P, Daniel WA: Characterization of human cytochrome p450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab. Dispos. 34(3), 471-476 (2006). (Pubitemid 43290906)
4. LLerena A, Berecz R, de la Rubia A, Norberto MJ, Benítez J: Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther. Drug Monit. 22(4), 397-401 (2000). ■ Demonstrated the use of the mesoridazine:thioridazine ratio as a useful tool to assess CYP2D6 activity during treatment.
5. LLerena A, Berecz R, de la Rubia A, Fernández-Salguero P, Dorado P: Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. Ther. Drug Monit. 23(6), 616-620 (2001).
6. Berecz R, de la Rubia A, Dorado P, Fernández-Salguero P, Dahl ML, LLerena A: Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. 59(1), 45-50 (2003). ■ Showed that the plasma concentrations of thioridazine and its metabolites were influenced by the CYP2D6 genotype, and supported the dose-dependent inhibition of CYP2D6 by thioridazine. (Pubitemid 36702758)
7. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274(1), 516-520 (1995).
8. Chen S, Chou WH, Blouin RA et al.: The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin. Pharmacol. Ther. 60(5), 522-534 (1996). (Pubitemid 26414088)
9. Sachse C, Brockmöller J, Bauer S, Roots I: Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60(2), 284-295 (1997). (Pubitemid 27058401)
10. Griese EU, Zanger UM, Brudermanns U et al.: Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8(1), 15-26 (1998). (Pubitemid 28097597)
11. Zanger UM, Fischer J, Raimundo S et al.: Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 11(7), 573-585 (2001). ■ In this study the CYP2D6 -1584 C>G promoter polymorphism was identified as major factor for expression, and the mutant -1584G promoter type with significantly higher expression than -1584C.
12. Gaedigk A, Ryder DL, Bradford LD, Leeder JS: CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin. Chem. 49(6), 1008-1011 (2003). ■ Results of this study supported the idea that poor metabolism could be excluded by genotyping for CYP2D6 -1584C>G.
13. Chou WH, Yan FX, Robbins-Weilert DK et al.: Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin. Chem. 49(4), 542-551 (2003).
14. Ikenaga Y, Fukuda T, Fukuda K et al.: The frequency of candidate alleles for CYP2D6 genotyping in the Japanese population with an additional respect to the -1584C to G substitution. Drug Metab. Pharmacokinet. 20(2), 113-116 (2005).
15. Luo HR, Gaedigk A, Aloumanis V, Wan YJ: Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur. J. Clin. Pharmacol. 61(11), 797-802 (2005). (Pubitemid 41722129)
16. Müller B, Zöpf K, Bachofer J, Steimer W: Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin. Chem. 49(10), 1624-1631 (2003). (Pubitemid 37194216)
17. Gershon S, Sakalis G, Bowers PA: Mesoridazine: a pharmacodynamic and pharmacokinetic profile. J. Clin. Psychiatry 42(12), 463-469 (1981).
18. Raimundo S, Fischer J, Eichelbaum M, Griese E-U, Schwab M, Zanger UM: Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10(7), 577-581 (2000).
19. Raimundo S, Toscano C, Klein K et al.: A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin. Pharmacol. Ther. 76(2), 128-138 (2004). ■ Study revealed that a SNP in intron 6 (2988G>A) resulted in a subset of alleles to encode for slower metabolism. (Pubitemid 39013403)
20. Gaedigk A, Ndjountché L, Leeder JS, Bradford LD: Limited association of the 2988G>A single nucleotide polymorphism with CYP2D6*41 in black subjects. Clin. Pharmacol. Ther. 77(3), 228-230 (2005).
21. LLerena A, Berecz R, de la Rubia A, Dorado P: QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J. Psychopharmacol. 16(4), 361-364 (2002). ■ Relationship between CYP2D6 genetic polymorphism and QTc interval lengthening.
22. Dorado P, Berecz R, Peñas-LLedó EM, LLerena A: Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. Expert Opin. Drug Metab. Toxicol. 3(1), 9-19 (2007).
23. Hale PW Jr, Poklis A: Cardiotoxicity of thioridazine and two stereoisomeric forms of thioridazine 5-sulfoxide in the isolated perfused rat heart. Toxicol. Appl. Pharmacol. 86(1), 44-55 (1986).